Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma

American Journal of Surgical Pathology

Volumn 30, Issue 9, 2006, Pages 1175-1183

  Ogino, Shuji ^a,b,c   Odze, Robert D ^a,c   Kawasaki, Takako ^b   Brahmandam, Mohan ^b   Kirkner, Gregory J ^a   Laird, Peter W ^d   Loda, Massimo ^a,b,c   Fuchs, Charles S ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Colon cancer; Epigenetics; Histopathology; Hypermethylation; Promoter

Indexed keywords

ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; CROHN DISEASE; DNA DETERMINATION; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; METHYLATOR PHENOTYPE; MICROSATELLITE INSTABILITY; MUCINOUS CARCINOMA; PATHOLOGY; PHENOTYPE; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA; TUMOR NECROSIS;

CELL DIFFERENTIATION; COHORT STUDIES; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; HUMANS; LYMPHOCYTES; MICROSATELLITE REPEATS; NECROSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES;

EID: 33748040054     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000213266.84725.d0     Document Type: Article

References (43)

1. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527-535.
2. Anacleto C, Leopoldino AM, Rossi B, et al. Colorectal cancer "methylator phenotype": fact or artifact? Neoplasia. 2005;7:331-335.
3. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257.
4. Chirieac LR, Shen L, Catalano PJ, et al. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol. 2005;29:429-436.
5. Cottrell SE, Distler J, Goodman NS, et al. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 2004;32:e10.
6. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28:E32.
7. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59:2302-2306.
8. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000;60:5021-5026.
9. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001;61:3410-3418.
10. Frigola J, Sole X, Paz MF, et al. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet. 2005;14:319-326.
11. Fuchs CS, Willett WC, Colditz GA, et al. The influence of folate and multivitamin use on the familial risk of colon cancer in women. Cancer Epidemiol Biomarkers Prev. 2002;11:227-234.
12. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. 2004;23:11-27.
13. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol. 1990;3:332-335.
14. Hamilton SR, Vogelstein B, Kudo S. Carcinoma of the colon and rectum. Pathology and genetics of tumours of the digestive system. In: Aaltonen LA, Hamilton SR, eds. World Health Organization Classification of Tumours. Lyon: IARC Press; 2000.
15. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122:1376-1387.
16. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826.
17. Hibi K, Nakayama H, Kodera Y, et al. CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Br J Cancer. 2004;90:1030-1033.
18. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988-993.
19. Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology. 2005;129:1121-1124.
20. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol. 2005;2:398-405.
21. Jass JR, Ajioka Y, Allen JP, et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology. 1996;28:543-548.
22. Kambara T, Simms LA, Whitehall VLJ, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137-1144.
23. Kanazawa T, Watanabe T, Kazama S, et al. Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer. 2002;102:225-229.
24. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23:29-39.
25. Laird PW. Cancer epigenetics. Hum Mol Genet. 2005;14:R65-R76.
26. Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol. 2004;22:4584-4594.
27. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucious component. Mod Pathol. 2006;19:59-68.
28. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006. In press (published online first on January 11, 2006: doi:2010.1136/gut.2005.082933).
29. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7:413-421.
30. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of sodium bisulfite conversion and realtime PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006;8:209-217.
31. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005;11:6650-6656.
32. Redston M. Carcinogenesis in the GI tract: from morphology to genetics and back again. Mod Pathol. 2001;14:236-245.
33. Samowitz W, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129:837-845.
34. Shia J, Ellis NA, Paty PB, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003;27:1407-1417.
35. Thomassin H, Kress C, Grange T. MethylQuant: a sensitive method for quantifying methylation of specific cytosines within the genome. Nucleic Acids Res. 2004;32:e168.
36. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681-8686.
37. Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000;97:710-715.
38. van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 2003;9:2898-2903.
39. van Rijnsoever M, Grieu F, Elsaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002;51:797-802.
40. Whitehall VL, Wynter CV, Walsh MD, et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res. 2002;62:6011-6014.
41. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004;64:3807-3813.
42. Yamashita K, Dai T, Dai Y, et al. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell. 2003;4:121-131.
43. Zeschnigk M, Bohringer S, Price EA, et al. A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. Nucleic Acids Res. 2004;32:e125.